Submit your requirements and our technical
team will help.
| プロジェクト | 薬物タイプ | 治療分野 | 適応症 | ステージ | エリア |
|---|---|---|---|---|---|
| Her2xCD3 BsAb | Bispecific antibody | Oncology/Cancer | HER2-positive Cancer | Phase I | Global |
| Anti-Her2 II / Anti-Her2 IV Bi-specific antibody ADC | Bioconjugates | Oncology/Cancer | Solid tumor | Preclinical | Global |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) | SIBP-01 | Phase 3 Clinical | Shanghai Institute of Biological Products Co Ltd | Breast Neoplasms; Stomach Neoplasms | 詳細 |
| Anvatabart opadotin | NCB-001; JNJ-0683; ARX-788 | Phase 3 Clinical | Ambrx Inc | Bile Duct Neoplasms; Breast Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | 詳細 |
| Sacibertinib | Hemay-022 | Phase 3 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd | Breast Neoplasms; Foodborne Diseases | 詳細 |
| Pertuzumab biosimilar(Hisun Pharm) | HS-627; HS627 | Phase 3 Clinical | Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd | Breast Neoplasms | 詳細 |
| Recombinant human neuregulin-1 | rhNRG-1 | Phase 3 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Myocardial Infarction | 詳細 |
| Caxmotabart Entudotin | FS-1502; LCB14-0110; LCB-14-0110; IKS014; IKS-014; LCB-14 | Phase 3 Clinical | Legochembio | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Solid tumours; Stomach Neoplasms | 詳細 |
| HLX-22 | AC-101; HLX-22; HLX22 | Phase 3 Clinical | Atlas Therapeutics AB | Breast Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Coprelotamab | GB-221 | Phase 3 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms; Metastatic breast cancer | 詳細 |
| Trastuzumab vedotin | MRG-002 | Phase 3 Clinical | Shanghai Miracogen Inc | Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Solid tumours; Stomach Neoplasms | 詳細 |
| trastuzumab biosimilar (Hetero) | Ado-Trastuzumab biosimilar (Hetero) | Phase 3 Clinical | Hetero Drugs Ltd | Neoplasms | 詳細 |
| T‑Bren | BLM07D1; BL-M07D1 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Urogenital Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| Pertuzumab biosimilar(Zydus Cadila) | ZRC-3277 | Phase 3 Clinical | Zydus Cadila | Metastatic breast cancer | 詳細 |
| HL-02 | HL-02 | Phase 3 Clinical | Hualan Ankang Biotechnology Co Ltd | Breast Neoplasms | 詳細 |
| JSKN-003 | JSKN-003 | Phase 3 Clinical | Alphamab Oncology | Breast Neoplasms; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Diseases; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Diseases; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Trastuzumab biosimilar (Hetero Biopharma) | Phase 3 Clinical | Hetero Biopharma Ltd | Breast Neoplasms | 詳細 | |
| Ado Trastuzumab Emtansine biosimilar (Hetero Biopharma) | HBP 6 | Phase 3 Clinical | Hetero Biopharma Ltd | Breast Neoplasms | 詳細 |
| IBI-354 | IBI-354 | Phase 3 Clinical | Breast Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Ovarian Diseases; Ovarian Neoplasms; Peritoneal Diseases; Peritoneal Neoplasms; Solid tumours | 詳細 | |
| TQB-2102 | TQB2102; TQB-2102 | Phase 3 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Genital Neoplasms, Female; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| TQB-2930 | TQB-2930 | Phase 3 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Breast Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours | 詳細 |
| HER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology) | GLSI-100 | Phase 3 Clinical | Antigen Express Inc, Norwell Inc | Breast Neoplasms | 詳細 |
| Trastuzumab pamirtecan | DB-1303; BNT323 | Phase 3 Clinical | Duality Biologics (Suzhou) Co Ltd | Breast Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Solid tumours | 詳細 |
| GQ-1005 | GQ-1005; GQ1005 | Phase 3 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | 詳細 |
| Trastuzumab biosimilar(Aprogen/Nichi-Iko) | AP-06 | Phase 3 Clinical | Aprogen, Nichi-Iko Pharmaceutical Co Ltd | Breast Neoplasms | 詳細 |
| Pertuzumab biosimilar (Xuanzhu/SL) | KM-118; KM118; XZP-KM118 | Phase 3 Clinical | Beijing Sl Pharmaceutical Co Ltd, Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Breast Neoplasms | 詳細 |
| Pertuzumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Breast Neoplasms | 詳細 | |
| IAH-0968 | IAH0968; IAH-0968 | Phase 3 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Biliary Tract Neoplasms; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| BAT-1006 | BAT-1006 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Breast Neoplasms; Solid tumours | 詳細 |
| Trastuzumab envedotin | DP-303c; DP303c; SYSA1501; SYSA-1501 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Breast Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Neoplasms; Ovarian Neoplasms; Salivary Gland Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Solid tumours | 詳細 |
| DF-1001 | DF-1001 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours | 詳細 |
| TPIV-100 (TapImmune) | TPIV-100 | Phase 2 Clinical | Mayo Clinic | Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Intraductal, Noninfiltrating | 詳細 |
| BB-1701 | BB-1701 | Phase 2 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Metastatic breast cancer; Solid tumours; Stomach Neoplasms | 詳細 |
| Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Plc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) | Phase 2 Clinical | Huazhong University Of Science And Technology, Medimmune, University Of Michigan, University Of Virginia Cancer Center | Breast Neoplasms | 詳細 | |
| RG-6596 | ZN-1041; RG-6596; ZN-A-1041 | Phase 2 Clinical | Suzhou Zanrong Pharmaceutical Technology Co Ltd | Breast Neoplasms; Solid tumours | 詳細 |
| AU-101 | AU-101 | Phase 2 Clinical | Attralus Inc | Breast Neoplasms; Glioblastoma; Osteosarcoma | 詳細 |
| Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Neoplasm Metastasis; Neoplasms; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive | 詳細 |
| DX126-262 | DAC-001; DX126-262 | Phase 2 Clinical | Hangzhou Dac Biotech Company Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Metastatic breast cancer; Stomach Neoplasms | 詳細 |
| AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 2 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | 詳細 |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 詳細 |
| Cinrebafusp alfa | PRS-343 | Phase 2 Clinical | Pieris Pharmaceuticals | Breast Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms | 詳細 |
| AU-105 | AU-105 | Phase 2 Clinical | Attralus Inc | Glioblastoma | 詳細 |
| Varlitinib Ditosylate | SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 | Phase 2 Clinical | Array Biopharma | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | 詳細 |
| HER2 cancer vaccine (BioLife Science) | PEV-6; PEV-6A; IMU-131 | Phase 2 Clinical | Pevion Biotech Ltd | Adenocarcinoma; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Stomach Neoplasms | 詳細 |
| AE-37/GP-2 vaccine | AE-37 (Generex Biotechnology Corporation) | Phase 2 Clinical | Generex Biotechnology Corp | Breast Neoplasms; Triple Negative Breast Neoplasms | 詳細 |
| ADXS-31164 | Lovaxin B; OST-HER2; OST31-164; ADXS31-164; ADXS-31164; ADXS-cHER2; ADXS-HER2 | Phase 2 Clinical | University Of Pennsylvania | Bone Neoplasms; Solid tumours | 詳細 |
| Enozertinib | ORIC-114; VRN-07 | Phase 2 Clinical | Voronoi Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | 詳細 |
| Nesfrotamig | ABL105; YH-32367 | Phase 2 Clinical | Abl Bio Inc | Breast Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| EB-DT-CAR-NK | EB-DT-CAR-NK | Phase 2 Clinical | Beijing Biotech | Breast Neoplasms; Triple Negative Breast Neoplasms | 詳細 |
| EB-DuoNK-MSLN/HER2 cell therapy (Beijing Biotech) | Phase 2 Clinical | Beijing Biotech | Carcinoma, Non-Small-Cell Lung | 詳細 | |
| HER2 FPBMC therapy (University Of Virginia) | HER2 FPBMC | Phase 2 Clinical | University Of Virginia | Breast Neoplasms; Prostatic Neoplasms | 詳細 |
| CLIO-8221 | HMBD-802; HMBD802; CLIO8221; CLIO-8221 | Phase 2 Clinical | Hummingbird Bioscience | Solid tumours | 詳細 |
| 99mTc-ZHER2:41071 | Phase 2 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | 詳細 | |
| 68-GaNOTA-Anti-HER2 VHH1 | Phase 2 Clinical | Universitair Ziekenhuis Brussel | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Salivary Gland Neoplasms; Stomach Neoplasms; Uterine Neoplasms | 詳細 | |
| HMPL-A251 | HMPLA251; HMPL-A251 | Phase 2 Clinical | Solid tumours | 詳細 | |
| Pertuzumab biosimilar (Peking Union Medical College Hospital) | Phase 2 Clinical | Peking Union Medical College Hospital | Rectal Neoplasms | 詳細 | |
| Trastuzumab biosimilar (Peking Union Medical College Hospital) | Phase 2 Clinical | Peking Union Medical College Hospital | Rectal Neoplasms | 詳細 | |
| HER2 targeting chimeric antigen receptor T cell therapy (Essen Biotech) | Phase 2 Clinical | Essen Biotech | Osteosarcoma; Sarcoma; Sarcoma, Ewing; Sarcoma, Kaposi; Sarcoma, Synovial | 詳細 | |
| SYS-6045 | SYS6045; SYS-6045 | Phase 2 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours | 詳細 |
| YH-42946 | YH42946; YH-42946 | Phase 2 Clinical | Yuhan Corp | Carcinoma, Non-Small-Cell Lung; Solid tumours | 詳細 |
| Neratinib (Fukang (Shanghai) Health Technology) | CVL009; CVL-009 | Phase 2 Clinical | Convalife (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours; Uterine Neoplasms | 詳細 |
| JSKN-033 | JSKN033; JSKN-033; JSKN-003/Envafolimab | Phase 2 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | 詳細 |
| SHR-4602 | SHR-4602; SHR4602 | Phase 2 Clinical | Shanghai Suncadia Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Solid tumours | 詳細 |
| HER2 Targeted HypoSti.CAR-T Cells(Chinese PLA General Hospital) | Phase 2 Clinical | Fudan University, Pla General Hospital | Solid tumours | 詳細 | |
| FDA022 Antibody Drug Conjugate | FDA022-BB05; F0034 | Phase 2 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Breast Neoplasms; Solid tumours | 詳細 |
| I-025-A | I-025-A | Phase 2 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms; Colorectal Neoplasms | 詳細 |
| BAT-8010 | BAT-8010; BAT8010 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours | 詳細 |
| RAD-201 | RAD-201 | Phase 2 Clinical | Radiopharm Theranostics Ltd | Breast Neoplasms | 詳細 |
| ST-1703 | ST-1703 | Phase 2 Clinical | Beijing Scitech-Mq Pharmaceuticals Ltd | Metastatic breast cancer; Solid tumours | 詳細 |
| TL-938 | TL-938 | Phase 2 Clinical | Suzhou Teligene Ltd | Colorectal Neoplasms; Neoplasms | 詳細 |
| SSGJ-705 | SSGJ-705; 705 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Neoplasms; Solid tumours | 詳細 |
| EO-1001 | NT-113; APL-122 | Phase 2 Clinical | Edison Pharmaceuticals Inc | Neoplasms | 詳細 |
| SPH-5030 | SPH-5030 | Phase 2 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Colorectal Neoplasms; Solid tumours | 詳細 |
| IMM-2902 | IMM-2902 | Phase 2 Clinical | Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 | |
| Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab) | HuA21; HuA-21 | Phase 2 Clinical | Hefei Hankemab Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms | 詳細 |
| JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | 詳細 |
| AIP-303 | AIP-303 | Phase 2 Clinical | Advanced Imaging Projects | Breast Neoplasms | 詳細 |
| GQ-1001 | GQ-1001 | Phase 2 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Biliary Tract Neoplasms; Breast Neoplasms; Metastatic breast cancer; Solid tumours | 詳細 |
| Epertinib | S-222611; RT1978; RT-1978 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | 詳細 |
| Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours | 詳細 |
| Gancotamab | MM-302 | Phase 2 Clinical | Merrimack Pharmaceuticals Inc | Breast Neoplasms; Ovarian Neoplasms | 詳細 |
| Anti-CD3-anti-HER2-activated T cells | Phase 2 Clinical | Transtarget | Bone metastases; Breast Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 詳細 | |
| anti-HER2 ADC (Pfizer) | PF-06804103 | Phase 2 Clinical | Pfizer Inc | Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms | 詳細 |
| ETBX-021 | ETBX-021 | Phase 2 Clinical | Etubics Corp, Nantbioscience Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Squamous Cell Carcinoma of Head and Neck | 詳細 |
| HER2(EQ)BBzeta/CD19 T cells (City of Hope) | Phase 1 Clinical | City Of Hope National Medical Center, Mustang Bio Inc | Glioma | 詳細 | |
| RG-6148 | RG-6148; DHES-0815A | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Breast Neoplasms | 詳細 |
| CIDeCAR | Phase 1 Clinical | Bellicum Pharmaceuticals Inc, National Cancer Institute | Osteosarcoma | 詳細 | |
| SC-CAR4BRAIN | Phase 1 Clinical | Seattle Children'S Hospital | Carcinoma; Carcinoma, Hepatocellular; Central Nervous System Neoplasms; Desmoplastic Small Round Cell Tumor; Diffuse Intrinsic Pontine Glioma; Diffuse midline glioma; Endodermal Sinus Tumor; Hepatoblastoma; Liposarcoma; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neurofibrosarcoma; Osteosarcoma; Retinoblastoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Clear Cell; Sarcoma, Ewing; Sarcoma, Synovial; Solid tumours; Wilms Tumor | 詳細 | |
| 99m-Tc labeled anti-HER2 single domain antibody (NanoMab) | 99mTc-NM-02 | Phase 1 Clinical | Nanomab Technology Ltd | Breast Neoplasms | 詳細 |
| GB-235 | GB-235 | Phase 1 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms | 詳細 |
| HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) | Phase 1 Clinical | National Cancer Institute, University Of Pennsylvania | Breast Neoplasms | 詳細 | |
| Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) | B-003 (Shanghai Pharma) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | 詳細 |
| MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | 詳細 |
| TAS-0728 | TPC-107; TAS-0728 | Phase 1 Clinical | Taiho Pharmaceutical Co Ltd | Solid tumours | 詳細 |
| 68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles) | Phase 1 Clinical | Universite Libre De Bruxelles | Breast Neoplasms | 詳細 | |
| KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | 詳細 |
| Recombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon) | LZM-005 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Breast Neoplasms | 詳細 |
| MX-402 | MX-402 | Phase 1 Clinical | Medvax Technologies | Stomach Neoplasms | 詳細 |
| MB-103 | MB-103 HER2 CAR; MB-103; HER2(EQ)BBζ/CD19t+ Tcm; HER2-BBζ CAR-T cells | Phase 1 Clinical | City Of Hope National Medical Center | Brain metastases; Breast Neoplasms; Glioblastoma; Meningeal Neoplasms; Neoplasms | 詳細 |
| Fidasimtamab | IBI-315; BH-2950 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Neoplasms; Solid tumours | 詳細 |
| Trastuzumab biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Breast Neoplasms; Stomach Neoplasms | 詳細 | |
| Recombinant anti-HER2 humanized monoclonal antibody complex | B-002 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms; Metastatic breast cancer | 詳細 |
| Runimotamab | RO-7227780; BTRC-4017A; RG-6194 | Phase 1 Clinical | Genentech Inc | Solid tumours | 詳細 |
| KSP-910638-G | KSP-910638G; KSP-910638-G | Phase 1 Clinical | University Of Michigan | Gastrointestinal Neoplasms | 詳細 |
| TT-16 | TT-16 | Phase 1 Clinical | Tessa Therapeutics Ltd | Solid tumours | 詳細 |
| Ado-trastuzumab emtansine biosimilar (Jiangsu Hengrui Medicine) | SHR-A1201 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Breast Neoplasms | 詳細 |
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | M-802 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd, Wuhan Yzy Biopharma Co Ltd | Breast Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Autologous-HER2-specific-T-cells | Autologous-HER2-specific-T-cells | Phase 1 Clinical | Baylor College Of Medicine | Brain Neoplasms; Sarcoma | 詳細 |
| Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) | HS-630; HS630 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd | Breast Neoplasms | 詳細 |
| Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | 詳細 | |
| Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Research Institute | Central Nervous System Neoplasms | 詳細 | |
| [89Zr]-Df-Trastuzumab | Phase 1 Clinical | University Of Alabama At Birmingham | Breast Neoplasms; Neoplasms; Solid tumours | 詳細 | |
| KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | 詳細 | |
| Pertuzumab biosimilar(SL Pharma/Combio) | Phase 1 Clinical | Beijing Kangming Bio New Drug Development Co Ltd, Beijing Sl Pharmaceutical Co Ltd | Breast Neoplasms; Inflammatory Breast Neoplasms; Metastatic breast cancer | 詳細 | |
| ZV-0203 | ZV-0203; ZV203; ADC2122; ZV0203; ADC 2122 | Phase 1 Clinical | Hangzhou Adcoris Biopharmacy Co Ltd | Solid tumours | 詳細 |
| 4-1BBz CD19-Her2tG (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma; Neoplasms | 詳細 | |
| HER2.taNK | NK-92/5.28.z | Phase 1 Clinical | Nantkwest Inc | Glioblastoma | 詳細 |
| PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | 詳細 |
| Trastuzumab biosimilar (BioIntegrator) | BI-Mab-03 | Phase 1 Clinical | Biointegrator Llc | Breast Neoplasms | 詳細 |
| BAY-2701438 | BAY-2701438 | Phase 1 Clinical | Bayer AG | Neoplasms | 詳細 |
| Neptinib Di-P-methylbenzenesulfonate | Phase 1 Clinical | Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Stomach Neoplasms | 詳細 | |
| GB-251 | GB-251; NBT-828; GB221-NBT828 ADC-1 | Phase 1 Clinical | Genor Biopharma Co Ltd, Newbio Therapeutics Inc | Breast Neoplasms; Metastatic breast cancer | 詳細 |
| HER.CAR-CMV-specific-CTLs | HER.CAR-CMV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Glioblastoma | 詳細 |
| ALT-P7 | HM2-MMAE; ALT-P7 | Phase 1 Clinical | Alteogen Inc | Breast Neoplasms; Stomach Neoplasms | 詳細 |
| Trastuzumab imbotolimod | BDC-1001; Boltbody™ ISAC BDC-1001 | Phase 1 Clinical | Bolt Biotherapeutics Inc | Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours | 詳細 |
| anti-HER2 CAR macrophage therapy (The Affiliated Hospital of Xuzhou Medical University) | Phase 1 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms | 詳細 | |
| anti-HER2 CAR T-cell therapy (Shanghai First Song Therapeutics) | Phase 1 Clinical | Shanghai Simcere Pharmaceutical Co Ltd | Colorectal Neoplasms; Metastatic breast cancer; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 | |
| EX-101 (Excelmab) | Phase 1 Clinical | ExcelMab Inc | Breast Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 | |
| MHC class II HER-2/neu antigen vaccine (Marker Therapeutics) | Phase 1 Clinical | Mayo Clinic | Breast Neoplasms | 詳細 | |
| dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms | 詳細 | |
| SHR-1904 | SHR-1904 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Pancreatic Neoplasms; Solid tumours | 詳細 |
| [177Lu]Lu-ABY-271 | 177Lu-ABY-271 | Phase 1 Clinical | Affibody Medical AB | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Metastatic breast cancer; Ovarian Neoplasms; Stomach Neoplasms | 詳細 |
| Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Adenocarcinoma; Breast Neoplasms; Neoplasm Metastasis; Neoplasms | 詳細 | |
| VRN-10 | VRN-101099; VRN-10 | Phase 1 Clinical | Voronoi Inc | Neoplasms; Solid tumours | 詳細 |
| NC-18 | NC-18 | Phase 1 Clinical | Novacyte Therapeutics Company Ltd | Solid tumours | 詳細 |
| BC-004 | BC-004 | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Breast Neoplasms; Solid tumours | 詳細 |
| Trastuzumab biosimilar (United BioPharma) | UB-921 | Phase 1 Clinical | United Biopharma Inc | Breast Neoplasms | 詳細 |
| TGFBeta-resistant-HER2-EBV-CTLs | TGFBeta-resistant-HER2-EBV-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Neoplasms | 詳細 |
| NeuCeptin | NeuCeptin | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Breast Neoplasms; Stomach Neoplasms | 詳細 |
| SAR-446309 | AMX-818; HER2-XPAT; SAR-446309; VIR-5818 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Neoplasms; Solid tumours | 詳細 |
| XMT-2056 | XMT-2056 | Phase 1 Clinical | Mersana Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Stomach Neoplasms | 詳細 |
| EB-DT-NK-UC101 | EB-DT-NK-UC101 | Phase 1 Clinical | Beijing Biotech | Carcinoma; Carcinoma, Transitional Cell; Urethral Neoplasms; Urinary Bladder Neoplasms | 詳細 |
| CAN-016 | CAN016; CAN-016 | Phase 1 Clinical | Conway (Guangzhou) Biotechnology Co Ltd | Solid tumours | 詳細 |
| Bmab-3000 | Bmab3000; Bmab-3000 | Phase 1 Clinical | Biocon Biologics UK Plc | 詳細 | |
| CGT-4255 | CGT-4255; CGT4255 | Phase 1 Clinical | Cogent Biosciences Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Solid tumours | 詳細 |
| 68Ga-SNA018 | 68Ga-SNA018; 68Ga-SNA-018; 68Ga-ADAPT6 | Phase 1 Clinical | Kth Royal Institute Of Technology, Uppsala University | Breast Neoplasms; Stomach Neoplasms | 詳細 |
| RR-M01 | RR-M01; BM-1901 | Phase 1 Clinical | Rock Roc Biotechnology Co Ltd | Solid tumours | 詳細 |
| 68Ga SGMIB-ZT-199 | 68Ga-SGMIB-ZT-199 | Phase 1 Clinical | Huashan Hospital | Breast Neoplasms | 詳細 |
| 188Re-NM-02 | 188Re-NM-02 | Phase 1 Clinical | NanoMab Technology (UK) Ltd, Shanghai Jiao Tong University Affiliated First People'S Hospital | Breast Neoplasms | 詳細 |
| 89Zr-LNCab072 | 89Zr-LNCab072 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Breast Neoplasms; Carcinoma, Transitional Cell; Stomach Neoplasms | 詳細 |
| 89Zr-LNCab002 | 89Zr-LNCab002 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Breast Neoplasms; Carcinoma, Transitional Cell; Stomach Neoplasms | 詳細 |
| 89Zr-LNCab190 | 89Zr-LNCab190 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Breast Neoplasms; Carcinoma, Transitional Cell; Stomach Neoplasms | 詳細 |
| 89Zr-LNCab104 | 89Zr-LNCab104 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Breast Neoplasms; Carcinoma, Transitional Cell; Stomach Neoplasms | 詳細 |
| 89Zr-LNCab103 | 89Zr-LNCab103 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Breast Neoplasms; Carcinoma, Transitional Cell; Stomach Neoplasms | 詳細 |
| [111In]In-DOTA-TCO-trastuzumab | Phase 1 Clinical | Radboud University Medical Center | Solid tumours | 詳細 | |
| TGW-211 | TGW-211; TRG001; TRG-001 | Phase 1 Clinical | Tagworks Pharmaceuticals BV | Breast Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| AK-2024 | AK2024; AK-2024; BSI-128 | Phase 1 Clinical | Biosion Inc | Solid tumours | 詳細 |
| SYS-6040 | SYS6040; SYS-6040 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| 177 Lu-RAD202 | 177 Lu-RAD202 | Phase 1 Clinical | Radiopharm Theranostics Ltd | Breast Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| GenSci-139 | GenSci-139; GenSci139 | Phase 1 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Zanidatamab zovodotin | ZW-49 | Phase 1 Clinical | Zymeworks Inc | Neoplasms | 詳細 |
| SYS-6041 | SYS6041; SYS-6041 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Neoplasms; Solid tumours | 詳細 |
| Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Stomach Neoplasms | 詳細 |
| BL-M17D1 | BL-M17D1; BL-M217D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Metastatic breast cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| NVL-330 | NVL-330 | Phase 1 Clinical | Nuvalent Inc | Neoplasms; Solid tumours | 詳細 |
| IAM-1363 | IAM-H1; ENT-H1; IAM1363; IAM-1363 | Phase 1 Clinical | Iambic Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms | 詳細 |
| Human HER2-targeted CAR-M cells therapy (Macera therapeutics) | Phase 1 Clinical | Nanjing Yuanmai Cell Biotechnology Co Ltd | Stomach Neoplasms | 詳細 | |
| AB-201(GC Cell) | Phase 1 Clinical | GC Cell Corp | Neoplasms | 詳細 | |
| MSH-2IA | MSH2IA; MSH-2IA | Phase 1 Clinical | Imagion Biosystems Ltd | Breast Neoplasms | 詳細 |
| SIBP-A17 | SIBP-A17; SIBPA17 | Phase 1 Clinical | Shanghai Institute of Biological Products Co Ltd | Solid tumours | 詳細 |
| Anti-HER2-CAR-T Cells Therapy(First Song Therapeutics) | Phase 1 Clinical | China Medical University, China, Shanghai First Song Therapeutics Co Ltd | Solid tumours | 詳細 | |
| [68Ga]ABY-025 | ABY-025; 68GaABY025; [68Ga]-ABY-025; ABY-025-[68Ga]; Gallium-68-ABY-025; [68Ga]Ga-ABY-025 PET | Phase 1 Clinical | Affibody Ab | Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasm Metastasis; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | 詳細 |
| 89Zr-DFO*Trastuzumab | Phase 1 Clinical | Astrazeneca Plc | Breast Neoplasms; Metastatic breast cancer; Stomach Neoplasms | 詳細 | |
| [123I] I-(HE)3-G3 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | 詳細 | |
| D3L-001 | D3L-001 | Phase 1 Clinical | D3 Bio (Wuxi) Co Ltd | Neoplasms; Solid tumours | 詳細 |
| KY-1702 | KY-1702; KY1702 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | 詳細 |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | 詳細 |
| XZP-KM501 | XZP-KM501; KM-501 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Neoplasm Metastasis; Solid tumours | 詳細 |
| SMP-656 | SMP-656 | Phase 1 Clinical | Chengdu Xilinglab Pharmaceutical Co Ltd | Neoplasms; Solid tumours | 詳細 |
| ELVN-002 | ELVN-002 | Phase 1 Clinical | Enliven Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Metastatic breast cancer; Solid tumours; Stomach Neoplasms | 詳細 |
| CPO-204 | CPO-204 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Carcinoma, Transitional Cell | 詳細 |
| 99mTc-MIRC213 | 99-mTc-MIRC-213 | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | 詳細 |
| TY4028 | TY-4028; TY4028 | Phase 1 Clinical | TYK Medicines Inc | Carcinoma, Non-Small-Cell Lung; Neoplasms | 詳細 |
| FT-825 | ONO-8250; FT-825; ONO 8250/FT 825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Solid tumours | 詳細 |
| Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | 詳細 |
| Allogeneic blood-derived NK cell therapy (NKGen Biotech) | SNK-02; SNK02; CAR-SNK-02 | Phase 1 Clinical | NKGen Biotech Inc | Neoplasm Metastasis; Neoplasms; Solid tumours | 詳細 |
| KMHH-03 | KMHH-03; KMHH03 | Phase 1 Clinical | Beijing Kangming Haihui Biological Technology Co Ltd | Breast Neoplasms | 詳細 |
| Pertuzumab biosimilar (biocad) | BCD-178 | Phase 1 Clinical | BIOCAD JSC | Breast Neoplasms | 詳細 |
| 99mTc- ADAPT6 | 99mTc- ADAPT6; ADAPT6; SNA-018; 99mTc-SNA-018 | Phase 1 Clinical | Kth Royal Institute Of Technology, Uppsala University | Breast Neoplasms | 詳細 |
| 99mTc-HE3-G3 | 99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3; 99mTc-(CO)3-(HE)3-Ec1; [99mTc]Tc(CO)3-(HE)3-Ec1 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms; Solid tumours | 詳細 |
| 227Th-Trastuzumab corixeta | BAY-2701439 | Phase 1 Clinical | Bayer AG | Neoplasms | 詳細 |
| XZP-KM257 | XZP-KM257; KM-257 | Phase 1 Clinical | Beijing Kangming Bio New Drug Development Co Ltd | Solid tumours | 詳細 |
| PM-3002 | PM-3002 | Phase 1 Clinical | 詳細 | ||
| XZP-5209 | XZP-5209 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | 詳細 |
| SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Breast Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| NIP-142 | NIP-142 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Carcinoma, Non-Small-Cell Lung | 詳細 |
| Anti-HER2 CAR T-cell therapy (Baylor College of Medicine/The Hospital for Sick Children/Texas Children's Hospital/The Methodist Hospital System ) | Phase 1 Clinical | Baylor College Of Medicine, Texas Children'S Hospital, The Hospital For Sick Children, The Methodist Hosp Research Institute | Sarcoma | 詳細 | |
| HER-2 Specific CAR T Cell | Phase 1 Clinical | Pediatric Brain Tumor Consortium (Pbtc), St. Jude Children'S Research Hospital | Ependymoma | 詳細 | |
| AB-201 (Artiva Biotherapeutics) | GCC2003; AB-201 (Artiva Biotherapeutics); GCC-2003 | Phase 1 Clinical | GC Cell Corp | Breast Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| 89Zr-ss-Pertuzumab | Phase 1 Clinical | Genentech Inc | Breast Neoplasms; Metastatic breast cancer | 詳細 | |
| SSGJ-612 | SSGJ-612 | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Neoplasms; Solid tumours | 詳細 |
| Pertuzumab biosimilar(EirGenix) | EG-1206A; EG-1206-A | Phase 1 Clinical | Eirgenix Inc | Breast Neoplasms | 詳細 |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms; Pleural Effusion, Malignant | 詳細 | |
| CT-0508 | CT-0508 | Phase 1 Clinical | Carisma Therapeutics Inc | Solid tumours | 詳細 |
| CCT303-406 | CCT3-HER2-0406; CCT303-406 | Phase 1 Clinical | BioAtla Inc | Breast Neoplasms; Ovarian Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms | 詳細 |
| EX-101 | EX-101; EX101 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | 詳細 |
| DZD-1516 | DZD-1516 | Phase 1 Clinical | Dizal (Jiangsu) Pharmaceutical Co Ltd | Breast Neoplasms; Metastatic breast cancer | 詳細 |
| MBS-301 | MBS-301 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Breast Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| FCN-411 | FCN-411 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | 詳細 | |
| ACE-1702 | ACE-1702 | Phase 1 Clinical | Acepodia Taiwan Subsidiary | Metastatic breast cancer; Neoplasm Metastasis; Solid tumours; Stomach Neoplasms | 詳細 |
| CX510 | CX510; CX-510 | Phase 1 Clinical | Hangzhou Aojin Biomedical Technology Co Ltd, Hangzhou Sanyintai Pharmaceutical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | 詳細 |
| Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) | Phase 1 Clinical | Shenzhen Main Luck Pharmaceuticals Inc | Breast Neoplasms | 詳細 | |
| Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Breast Neoplasms | 詳細 | |
| Trastuzumab biosimilar (BioXpress) | BXT-2318; BX-2318 | Clinical | Bioxpress Therapeutics Sa | Metastatic breast cancer; Stomach Neoplasms | 詳細 |
| IBPM003TZ (Inbiopro Solutions) | IBPM-003TZ | Clinical | Inbiopro Solutions | Breast Neoplasms | 詳細 |
| 99-mTc-ABH-2 | Clinical | Peking Union Medical College Hospital | Breast Neoplasms | 詳細 | |
| IBPM002BZ (Inbiopro Solutions) | IBPM-002BZ | Clinical | Inbiopro Solutions | Carcinoma, Renal Cell; Colorectal Neoplasms; Small Cell Lung Carcinoma | 詳細 |
| 131I SGMIB-ZT-199 | 131I-SGMIB-ZT-199 | Clinical | Huashan Hospital | Breast Neoplasms | 詳細 |
| 18F-HER2 PET | Clinical | First Affiliated Hospital Of Zhejiang University | Carcinoma, Transitional Cell | 詳細 | |
| [18F]F-RESCA-RB14 | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | 詳細 | |
| [68Ga]Ga-DOTA-H2D3 | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | 詳細 | |
| 68Ga-Her2-affibody | 68Ga-Her2-affibody | Clinical | The First Affiliated Hospital Of Beijing University | Neoplasms | 詳細 |
| Anti-HER2 CAR-T cell therapy (UTC Therapeutics) | Clinical | UTC Therapeutics Inc | Solid tumours | 詳細 | |
| 99mTc-DARPinG3 | 99mTc-DARPinG3; 99mTc-DARPinG-3 | Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | 詳細 |
| 99mTc-MIRC208 | Clinical | Beijing Cancer Hospital | Neoplasms | 詳細 | |
| [18F]GE-226 | GE-226-[18F]; Fluorine-18-GE-226; [18F]GE-226; 18F-GE-226 | Clinical | Affibody Ab | Breast Neoplasms | 詳細 |
| GW-2974 | GW-2974 | Glaxosmithkline Plc | Neoplasms | 詳細 | |
| [99mTc]Tc-G3-(G3S)3C | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | 泰瑞沙, Tagrisso | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Adenocarcinoma; Adenocarcinoma of Lung; Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Meningeal Neoplasms; Multiple Myeloma; Neoplasm, Residual; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 詳細 |
| Trastuzumab biosimilar (Celltrion) | CT-P6; CT-P06 | Approved | Celltrion Inc | Herzuma | South Korea | Stomach Neoplasms; Breast Neoplasms | null | 2014-01-01 | Breast Neoplasms; Metastatic breast cancer; Stomach Neoplasms | 詳細 |
| Trastuzumab emtansine biosimilar (Zydus Cadila) | ZRC-3256 | Approved | Zydus Cadila | Ujvira | India | Breast Neoplasms | Zydus Cadila | 2021-05-24 | Breast Neoplasms | 詳細 |
| Zanidatamab | JZP-598; ZW-25 | Approved | Zymeworks Inc | Ziihera, 百赫安 | United States | Biliary Tract Neoplasms | Jazz Pharmaceuticals Inc, Jazz Pharmaceuticals Plc | 2024-11-20 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Metastatic breast cancer; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Salivary Gland Neoplasms; Sarcoma; Stomach Neoplasms | 詳細 |
| Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) | HS-022 | Approved | Zhejiang Hisun Pharmaceutical Co Ltd | 安瑞泽 | Mainland China | Stomach Neoplasms; Breast Neoplasms | Hisun Biopharmaceutical Co Ltd | 2023-02-28 | Breast Neoplasms; Stomach Neoplasms | 詳細 |
| Trastuzumab biosimilar (Samsung Bioepis) | AMT-901; SB-3 | Approved | Samsung Bioepis Co Ltd | Samfenet, Ontruzant | EU | Breast Neoplasms; Stomach Neoplasms | Samsung Bioepis Nl Bv | 2017-11-15 | Breast Neoplasms; Stomach Neoplasms | 詳細 |
| Afatinib Dimaleate | BIBW-2992-MA2; BIBW-2992 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Giotrif, Tovok, 吉泰瑞, Tomtovok | United States | Carcinoma, Non-Small-Cell Lung | C.H. Boehringer Sohn Ag & Co. Kg | 2013-07-12 | Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chordoma; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Diseases; Lung Neoplasms; Lymphoma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Squamous Cell; Neuroectodermal Tumors; Penile Squamous Cell Carcinoma; Prostatic Neoplasms; Renal Insufficiency; Rhabdomyosarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Neoplasms | 詳細 |
| Trastuzumab biosimilar (Synthon) | ABP-980 | Approved | Synthon Bv | Kanjinti | EU | Breast Neoplasms; Stomach Neoplasms | Amgen Europe Bv | 2018-05-16 | Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Multiple Myeloma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 詳細 |
| Mifanertinib Maleate | MET-306 | Approved | Suzhou Maitai Bio-Technology Co Ltd | 迈瑞东 | Mainland China | Carcinoma, Non-Small-Cell Lung | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | 2025-10-21 | Carcinoma, Non-Small-Cell Lung; Solid tumours | 詳細 |
| Trastuzumab biosimilar (Zydus) | Approved | Zydus Cadila | Vivitra | India | Breast Neoplasms | Zydus Cadila | 2016-01-01 | Breast Neoplasms | 詳細 | |
| Margetuximab | MGAH-22 | Approved | Raven Biotechnologies Inc | Margenza | United States | Breast Neoplasms | Macrogenics Inc | 2020-12-16 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Ovarian Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | 詳細 |
| Trastuzumab/Pertuzumab | RO-7198574; RG-6264 | Approved | F. Hoffmann-La Roche Ltd | Phesgo, 赫捷康 | United States | Breast Neoplasms | Genentech Inc | 2020-06-29 | Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer | 詳細 |
| Trastuzumab biosimilar (Reliance Life Sciences) | R-TPR-016 | Approved | Reliance Life Sciences | TrastuRel | India | Breast Neoplasms | Reliance Life Sciences | 2015-01-01 | Breast Neoplasms | 詳細 |
| Trastuzumab biosimilar (Anke Biotech) | Approved | Anhui Anke Biotechnology (Group) Co Ltd | Mainland China | Breast Neoplasms | Anhui Anke Biotechnology (Group) Co Ltd | 2023-10-27 | Breast Neoplasms | 詳細 | ||
| Trastuzumab biosimilar (Hanwha Biologics) | HD-201 | Approved | Hanwha Biologics | Tuznue, Hervelous | EU | Breast Neoplasms; Stomach Neoplasms | Prestige BioPharma Ltd | 2024-09-19 | Breast Neoplasms; Stomach Neoplasms | 詳細 |
| Inetetamab | CMAB-302; 302(3SBio); 302H | Approved | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Cipterbin, 赛普汀 | Mainland China | Breast Neoplasms | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 2020-06-17 | Breast Neoplasms; Metastatic breast cancer | 詳細 |
| Trastuzumab biosimilar (Pfizer) | PF-5280014; PF-05280014 | Approved | Pfizer Inc | Trazimera, trastuzumab-qyyp | EU | Breast Neoplasms; Stomach Neoplasms | Pfizer Europe Ma Eeig | 2018-07-26 | Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Multiple Myeloma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 詳細 |
| Trastuzumab biosimilar (Alteogen) | ALT-L2; ALT-02; QL-1701; ALT-LS2 | Approved | Alteogen Inc | Mainland China | Breast Neoplasms | Qilu Pharmaceutical Co Ltd | 2024-06-28 | Breast Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Stomach Neoplasms | 詳細 | |
| Trastuzumab biosimilar (CTTQ Pharma) | TQ-B211 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 赛妥 | Mainland China | Breast Neoplasms; Stomach Neoplasms | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-07-25 | Breast Neoplasms; Metastatic breast cancer; Stomach Neoplasms | 詳細 |
| Trastuzumab biosimilar (AXXO) | Approved | Axxo | Breast Neoplasms | 詳細 | ||||||
| Trastuzumab rezetecan | SHR-A1811 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾维达 | Mainland China | Carcinoma, Non-Small-Cell Lung | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2025-05-27 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Genital Neoplasms, Female; HR-positive breast cancer; Lymphangioma, Cystic; Metastatic breast cancer; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| Trastuzumab biosimilar (Biocon/Mylan) | Bmab-200; Myl-1401O; HerMyl-1401O | Approved | Biocon Ltd, Mylan Nv | CANMAb, Ogivri, Zedora, Hertraz | India | Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms | null | 2013-01-01 | Breast Neoplasms; Carcinoma, Ductal, Breast; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| Trastuzumab botidotin | A-166 | Approved | Sichuan Kelun Pharmaceutical Co Ltd | 舒泰莱 | Mainland China | Breast Neoplasms | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2025-10-14 | Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma, Mucinous; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Laryngeal Neoplasms; Lip Neoplasms; Liver Neoplasms; Lung Neoplasms; Metastatic breast cancer; Mouth Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rare Diseases; Rectal Neoplasms; Salivary Gland Neoplasms; Skin Neoplasms; Solid tumours; Stomach Neoplasms; Tongue Neoplasms; Tonsillar Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| Trastuzumab | R-597; RO45-2317; Anti-HER2/neu-MAb; huMAb4D5-8; RG-597; MKC-454 | Approved | Genentech Inc | Herceptin, 赫赛汀 | United States | Breast Neoplasms | Genentech Inc | 1998-09-25 | Adenocarcinoma; Breast Diseases; Breast Neoplasms; Carcinoma, Acinar Cell; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colonic Neoplasms; Endometrial Neoplasms; Ependymoma; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Meningeal Carcinomatosis; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Neoplastic Cells, Circulating; Prostatic Neoplasms; Salivary Gland Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vulvar Diseases | 詳細 |
| Trastuzumab biosimilar (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Breast Neoplasms | 詳細 | ||||||
| Tucatinib | ARRY-380; ONT-380; MK-7119 | Approved | Array Biopharma | Tukysa | United States | Breast Neoplasms | Seagen Inc | 2020-04-17 | Breast Neoplasms; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Hepatic Insufficiency; Meningeal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Stomach Neoplasms | 詳細 |
| Ado-trastuzumab emtansine | RG-3502; R-3502; T-DM1; PRO-132365; RO-5304020 | Approved | Genentech Inc | Kadcyla, 赫赛莱 | United States | Breast Neoplasms | Genentech Inc | 2013-02-22 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Hematologic Neoplasms; Lung Neoplasms; Lymphoma; Metastatic breast cancer; Multiple Myeloma; Neoplasm Metastasis; Pancreatic Neoplasms; Salivary Gland Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | 詳細 |
| Trastuzumab biosimilar (Dr. Reddy's Laboratories) | Approved | Dr.Reddy's Laboratories Ltd | Hervycta | India | Breast Neoplasms | Dr.Reddy's Laboratories Ltd | 2018-07-26 | Breast Neoplasms | 詳細 | |
| Zenocutuzumab | MCLA-128 | Approved | Merus Nv | Bizengri | United States | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Merus Nv | 2024-12-04 | Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | 詳細 |
| Pertuzumab | rhuMab-2C4; RO-4368451; R-1273; RG-1273; RO-4368451-F01; rhuMAb2C4; Ro 436-8451/F01; RO4368451 | Approved | F. Hoffmann-La Roche Ltd, Genentech Inc | 帕捷特, Perjeta, Omnitarg | United States | Breast Neoplasms | Genentech Inc | 2012-06-08 | Adrenal Gland Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Multiple Endocrine Neoplasia; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Trastuzumab/Hyaluronidase | Approved | Genentech Inc | Herceptin Hylecta | United States | Breast Neoplasms | Genentech Inc | 2019-02-28 | Breast Neoplasms | 詳細 | |
| Fam-trastuzumab deruxtecan | DS-8201a; DS-8201; VRN-101099; T-DXd | Approved | Daiichi Sankyo Co Ltd | Enhertu, 优赫得, 優赫得 | United States | Breast Neoplasms | Daiichi Sankyo Co Ltd | 2019-12-20 | Adenocarcinoma; Bile Duct Neoplasms; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Meningeal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Neoplasms, Glandular and Epithelial; Osteosarcoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | 詳細 |
| Trastuzumab biosimilar (Shanghai Henlius Biotech) | HLX-02 | Approved | Zercepac, 汉曲优, HERCESSI | EU | Breast Neoplasms; Stomach Neoplasms | Accord Healthcare Slu | 2020-07-27 | Breast Neoplasms; Neoplasms; Stomach Neoplasms | 詳細 | |
| Trastuzumab biosimilar (Biocad) | BCD-022 | Approved | BIOCAD JSC | HERtiCAD | Russian Federation | Breast Neoplasms | BIOCAD JSC | 2016-01-01 | Breast Neoplasms | 詳細 |
| Pertuzumab biosimilar (Shanghai Henlius Biotech) | HLX-11 | Approved | POHERDY | United States | Breast Neoplasms | Shanghai Henlius Biologics Co Ltd, Shanghai Henlius Biotech Inc | 2025-11-13 | Breast Neoplasms; Metastatic breast cancer | 詳細 | |
| Pertuzumab biosimilar (Hisun Biopharma) | Approved | Hisun Biopharmaceutical Co Ltd | 贝泽汀 | Mainland China | Breast Neoplasms | Hisun Biopharmaceutical Co Ltd | 2026-02-02 | Breast Neoplasms | 詳細 | |
| Trastuzumab biosimilar(Curateq Biologics) | BP02; BP-02 | Approved | CuraTeQ Biologics Pvt Ltd | EU | Stomach Neoplasms; Breast Neoplasms | CuraTeQ Biologics SRO | 2025-06-30 | Breast Neoplasms; Neoplasms; Stomach Neoplasms | 詳細 | |
| Neratinib Maleate | HKI-272; PF-0528767; WAY-179272; CAN-030; PB-272 | Approved | Pfizer Inc | Nerlynx, 贺俪安, 汉奈佳, 赫赛佳, Hernera | United States | Breast Neoplasms | Puma Biotechnology Inc | 2017-07-17 | Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Hepatic Insufficiency; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | 詳細 |
| Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | United States | Breast Neoplasms | Novartis Pharma Ag | 2007-03-13 | Abdominal Neoplasms; Adenocarcinoma; Astrocytoma; Bile Duct Neoplasms; Brain metastases; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Central Nervous System Neoplasms; CNS Embryonal Tumor; Colorectal Neoplasms; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hypopharyngeal Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Lip Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Medulloblastoma; Melanoma; Metastatic breast cancer; Mouth Neoplasms; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Gonadal Tissue; Neurofibromatosis 2; Neuroma, Acoustic; Nose Neoplasms; Oligoden | 詳細 |
| Trastuzumab biosimilar (EirGenix/Sandoz) | EG-12014; EGI 014A1; EGI-014 | Approved | Eirgenix Inc, Sandoz | EU | Breast Neoplasms; Stomach Neoplasms | Sandoz Gmbh | 2023-11-15 | Breast Neoplasms; Stomach Neoplasms | 詳細 | |
| Sevabertinib | BAY-2927088 | Approved | Bayer AG, Broad Institute, Harvard University | Hyrnuo | United States | Carcinoma, Non-Small-Cell Lung | Bayer Healthcare Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Llc | 2025-11-19 | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Liver Diseases; Neoplasm Metastasis; Solid tumours | 詳細 |
| Zongertinib | BI-1810631 | Approved | Boehringer Ingelheim International Gmbh | HERNEXEOS, 圣赫途 | United States | Carcinoma, Non-Small-Cell Lung | Boehringer Ingelheim Pharmaceuticals Inc | 2025-08-08 | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Liver Diseases; Lung Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Solid tumours; Stomach Neoplasms | 詳細 |
| Pertuzumab biosimilar (Qilu Pharmaceutical) | QL-1209; QL1209 | Approved | Qilu Pharmaceutical Co Ltd | 安赛珠 | Mainland China | Breast Neoplasms | Qilu Pharmaceutical Co Ltd | 2024-12-17 | Breast Neoplasms | 詳細 |
| Trastuzumab biosimilar (AryoGen Pharmed) | Approved | Aryogen Biopharma | AryoTrust | Breast Neoplasms; Stomach Neoplasms | 詳細 | |||||
| Pertuzumab biosimilar (CTTQ) | TQB-2440 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 帕乐坦 | Mainland China | Breast Neoplasms | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2024-12-17 | Breast Neoplasms | 詳細 |
| Disitamab Vedotin | RC-48-ADC; RC48-ADC; RC-48 | Approved | 爱地希, Aidixi | Mainland China | Stomach Neoplasms | RemeGen Co Ltd | 2021-06-08 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Diseases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Endometrial Neoplasms; Gastroesophageal Junction Neoplasms; Genital Diseases, Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Liver Neoplasms; Melanoma; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Paget Disease, Extramammary; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 詳細 | |
| Pyrotinib Maleate | BLTN; HTI-1001; SHR-1258 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Adenocarcinoma of Lung; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Dacomitinib | PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 | Approved | Pfizer Inc | Vizimpro | United States | Carcinoma, Non-Small-Cell Lung | Pfizer Inc | 2018-09-27 | Adenocarcinoma; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Glioblastoma; Head and Neck Neoplasms; Liver Diseases; Lung Neoplasms; Mouth Neoplasms; Neoplasm Metastasis; Neoplasms; Penile Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | 詳細 |




